Advertisement

Aspirin Treatment Effect and Association with PIK3CA Mutation in Breast Cancer: A Biomarker Analysis

      Abstract

      Background

      Studies suggest regular aspirin use decreases breast cancer (BRCA) risk, with high doses exerting an “anti-cancer” effect. Despite reports suggesting aspirin’s protective role in BRCA, no findings on aspirin dose association(s) with treatment outcomes have been reported, nor have any molecular subtype associations by which aspirin influences outcomes been elucidated. To interrogate aspirin’s effect and determine which populations may benefit from its use, we retrospectively explored data from 1227 patients with BRCA. In this population, 32 used high-dose aspirin (325 mg), 121 used low-dose aspirin (81 mg), and 1074 used no aspirin before and/or after diagnosis.

      Patients and Methods

      Several association tests were performed to examine the correlations of clinical variables and PIK3CA mutations from 45 patients with BRCA who used 81 mg of aspirin daily. Kaplan-Meyer survival curves and the log-rank test were utilized to compare survival outcome differences for aspirin dose, usage history, and PIK3CA mutation status. Cox proportional hazards models were used to compute the multivariate hazard ratio (HR) for death.

      Results

      Patients who regularly used high-dose aspirin (325 mg) had better survival outcomes than those who used low-dose aspirin (81 mg) (HR, 0.094; 95% confidence interval [CI], 0.014-0.62; P = .014). Patients who used aspirin post-diagnosis only achieved significant benefits in overall survival (HR, 0.082; 95% CI, 0.023-0.3; P = 1.39E-04). Also, a subgroup of patients in the low-dose, long-term aspirin group with a PIK3CA mutation showed a small beneficial effect (HR, 0.37; 95% CI, 0.04-3.25; P = .37).

      Conclusion

      High-dose aspirin after diagnosis may confer BRCA treatment benefits. Future studies should assess the comprehensive mechanism of aspirin for the PIK3CA mutant subgroup in a large study.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Breast Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Rothwell P.M.
        • Wilson M.
        • Price J.F.
        • Belch J.F.
        • Meade T.W.
        • Mehta Z.
        Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials.
        Lancet. 2012; 379: 1591-1601
        • Thun M.J.
        • Jacobs E.J.
        • Patrono C.
        The role of aspirin in cancer prevention.
        Nat Rev Clin Oncol. 2012; 9: 259-267
        • Algra A.M.
        • Rothwell P.M.
        Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials.
        Lancet Oncol. 2012; 13: 518-527
        • Schreinemachers D.M.
        • Everson R.B.
        Aspirin use and lung, colon, and breast cancer incidence in a prospective study.
        Epidemiology. 1994; 5: 138-146
        • Chen W.Y.
        • Holmes M.D.
        Role of aspirin in breast cancer survival.
        Curr Oncol Rep. 2017; 19: 48
        • Holmes M.D.
        • Chen W.Y.
        • Li L.
        • Hertzmark E.
        • Spiegelman D.
        • Hankinson S.E.
        Aspirin intake and survival after breast cancer.
        J Clin Oncol. 2010; 28: 1467-1472
        • Fraser D.
        • Sullivan F.
        • Thompson A.
        • McCowan C.
        Aspirin use and survival after the diagnosis of breast cancer: a population-based cohort study.
        Br J Cancer. 2014; 111: 623-627
        • Luo T.
        • Yan H.-M.
        • He P.
        • Luo Y.
        • Yang Y.-F.
        • Zheng H.
        Aspirin use and breast cancer risk: a meta-analysis.
        Breast Cancer Res Treat. 2012; 131: 581-587
        • Lazzeroni M.
        • Petrera M.
        • Marra D.
        • DeCensi A.
        Aspirin and breast cancer prevention.
        Curr Breast Cancer Rep. 2013; 5: 202-207
        • Domingo E.
        • Church D.N.
        • Sieber O.
        • et al.
        Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer.
        J Clin Oncol. 2013; 31: 4297-4305
        • Liao X.
        • Lochhead P.
        • Nishihara R.
        • et al.
        Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival.
        N Engl J Med. 2012; 367: 1596-1606
        • Henry W.S.
        • Laszewski T.
        • Tsang T.
        • et al.
        Aspirin suppresses growth in PI3Kmutant breast cancer by activating AMPK and inhibiting mTORC1 signaling.
        Cancer Res. 2017; 77: 790-801
        • Khuder S.
        • Mutgi A.
        Breast cancer and NSAID use: a meta-analysis.
        Br J Cancer. 2001; 84: 1188-1192
        • Tang S.-C.
        • Shaheta N.
        • Chernenko G.
        • Khalifa M.
        • Wang X.
        Expression of BAG-1 in invasive breast carcinomas.
        J Clin Oncol. 1999; 17: 1710-1719
        • Kaplan E.L.
        • Meier P.
        Nonparametric estimation from incomplete observations.
        J Am Stat Assoc. 1958; 53: 457-481
        • Collett D.
        Modelling Survival Data in Medical Research.
        Chapman and Hall/CRC, New York2015
        • Pereira B.
        • Chin S.-F.
        • Rueda O.M.
        • et al.
        The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes.
        Nat Commun. 2016; 7: 11479
        • Curtis C.
        • Shah S.P.
        • Chin S.-F.
        • et al.
        The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups.
        Nature. 2012; 486: 346-352
        • Austin P.C.
        An introduction to propensity score methods for reducing the effects of confounding in observational studies.
        Multivariate Behav Res. 2011; 46: 399-424
        • Ho D.E.
        • Imai K.
        • King G.
        • Stuart E.A.
        MatchIt: nonparametric preprocessing for parametric causal inference.
        J Statistic Software. 2011; 42: 1-28
        • Friis S.
        • Sørensen H.T.
        • McLaughlin J.
        • Johnsen S.P.
        • Blot W.
        • Olsen J.
        A population based cohort study of the risk of colorectal and other cancers among users of low-dose aspirin.
        Br J Cancer. 2003; 88: 684-688
        • Flossmann E.
        • Rothwell P.M.
        • British Doctors Aspirin Trial and the UK-TIA Aspirin Trial
        Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies.
        Lancet. 2007; 369: 1603-1613
        • Goel S.
        • Krop I.E.
        PIK3CA mutations in HER2-positive breast cancer: an ongoing conundrum.
        Ann Oncol. 2016; 27: 1368-1372
        • Clarke C.A.
        • Canchola A.J.
        • Moy L.M.
        • et al.
        Regular and low-dose aspirin, other non-steroidal anti-inflammatory medications and prospective risk of HER2defined breast cancer: the California Teachers Study.
        Breast Cancer Res. 2017; 19: 52
        • Loi S.
        • Haibe-Kains B.
        • Majjaj S.
        • et al.
        PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor– positive breast cancer.
        Proc Natl Acad Sci U S A. 2010; 107: 10208-10213
        • Saal L.H.
        • Holm K.
        • Maurer M.
        • et al.
        PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma.
        Cancer Res. 2005; 65: 2554-2559
        • Loi S.
        • Michiels S.
        • Baselga J.
        • et al.
        PIK3CA genotype and a PIK3CA mutationrelated gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer.
        PLoS One. 2013; 8: e53292
        • Chandarlapaty S.
        • Sakr R.A.
        • Giri D.
        • et al.
        Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer.
        Clin Cancer Res. 2012; 18: 6784-6791
        • Cizkova M.
        • Dujaric M.
        • Lehmann-Che J.
        • et al.
        Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab.
        Br J Cancer. 2013; 108: 1807-1809
        • Hanker A.B.
        • Pfefferle A.D.
        • Balko J.M.
        • et al.
        Mutant PIK3CA accelerates HER2driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies.
        Proc Natl Acad Sci U S A. 2013; 110: 14372-14377
        • Chan A.T.
        • Giovannucci E.L.
        • Meyerhardt J.A.
        • Schernhammer E.S.
        • Wu K.
        • Fuchs C.S.
        Aspirin dose and duration of use and risk of colorectal cancer in men.
        Gastroenterology. 2008; 134: 21-28
        • Li P.
        • Wu H.
        • Zhang H.
        • et al.
        Aspirin use after diagnosis but not prediagnosis improves established colorectal cancer survival: a meta-analysis.
        Gut. 2015; 64: 1419-1425
        • Labelle M.
        • Begum S.
        • Hynes R.O.
        Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis.
        Cancer Cell. 2011; 20: 576-590
        • Akalay I.
        • Janji B.
        • Hasmim M.
        • et al.
        Epithelial-to-mesenchymal transition and autophagy induction in breast carcinoma promote escape from T cell-mediated lysis.
        Cancer Res. 2013; 73: 2418-2427
        • Cizkova M.
        • Susini A.
        • Vacher S.
        • et al.
        PIK3CA mutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroups.
        Breast Cancer Res. 2012; 14: R28
        • Kalinsky K.
        • Jacks L.M.
        • Heguy A.
        • et al.
        PIK3CA mutation associates with improved outcome in breast cancer.
        Clin Cancer Res. 2009; 15: 5049-5059
        • Li S.Y.
        • Rong M.
        • Grieu F.
        • Iacopetta B.
        PIK3CA mutations in breast cancer are associated with poor outcome.
        Breast Cancer Res Treat. 2006; 96: 91-95